AlzeCure Pharma AB (ALZCUR.BTA)
XSTO XSTO Primary XSTO Summary
ALZCUR.BTA Chart
AlzeCure Pharma AB (ALZCUR.BTA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has AlzeCure Pharma AB ever had a stock split?
AlzeCure Pharma AB Profile
| Biotechnology Industry | Healthcare Sector | - CEO | XSTO Exchange | - ISIN |
| Sweden Country | 11 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
AlzeCure Pharma AB (publ) is a pioneering pharmaceutical company focused on the development of innovative drug therapies tailored for severe diseases and conditions impacting the central nervous system. Since its establishment in 2012, with its base in Huddinge, Sweden, AlzeCure has embarked on a mission to address some of the most challenging neurological disorders. The company's dedication to scientific excellence is reflected in its versatile research platforms, namely NeuroRestore, Alzstatin, and Painless, which underline its commitment to addressing Alzheimer's disease, pain management, and a spectrum of central nervous system disorders through groundbreaking pharmacological approaches.
Products and Services
- ACD856
- ACD857, ACD679, and ACD680
- ACD440
- ACD137
Primarily targeted at Alzheimer's disease, ACD856 also holds promise for treating sleep disorders, depression, traumatic brain injuries, and Parkinson's disease. It is currently advancing through phase I clinical trials, highlighting AlzeCure's focus on neurodegenerative diseases and its commitment to improving quality of life for patients suffering from a range of central nervous system conditions.
These candidates are in the preclinical trial phase for Alzheimer's disease, representing AlzeCure's deep pipeline and ongoing investment in combating neurodegenerative disorders. Through extensive research and development, these drug candidates exemplify the company's strategy to offer novel treatments for Alzheimer's, aiming to halt or slow the progression of the disease.
A TRPV1 antagonist that has successfully completed phase I clinical trial for the indication of neuropathic pain. ACD440 represents AlzeCure's approach towards addressing pain management, providing hope for patients suffering from chronic pain conditions through innovative drug design and development.
Acting as a negative allosteric modulator (NAM) of TrkA receptors, ACD137 is tailored for osteoarthritic pain indications. This development underscores AlzeCure Pharma's commitment to expanding its pain management portfolio, offering new therapeutic options for patients with osteoarthritis and highlighting the company's expertise in targeting specific pain pathways.
